ANA- positive rates (ANA titer ≥ 1 +) in SLE group and non-SLE rheumatic diseases group were 96.62% and 50.47%, respectively, and the proportions of ANA 2 + or above (ANA titer ≥ 2 +) in the two groups were 86.49% and 30.91%, respectively, which were significantly higher than those in nephropathy group (6.06%, 0), hematological diseases group (10%, 0), or other diseases group (5.35%, 1.72%) (p < 0.01). The gene discussed is BTG3; the disease is kidney disorder.